CL2024002760A1 - Tratamiento de neurofibromas cutáneos con mirdametinib - Google Patents

Tratamiento de neurofibromas cutáneos con mirdametinib

Info

Publication number
CL2024002760A1
CL2024002760A1 CL2024002760A CL2024002760A CL2024002760A1 CL 2024002760 A1 CL2024002760 A1 CL 2024002760A1 CL 2024002760 A CL2024002760 A CL 2024002760A CL 2024002760 A CL2024002760 A CL 2024002760A CL 2024002760 A1 CL2024002760 A1 CL 2024002760A1
Authority
CL
Chile
Prior art keywords
mirdametinib
treatment
cutaneous neurofibromas
neurofibromas
cutaneous
Prior art date
Application number
CL2024002760A
Other languages
English (en)
Inventor
H Iloeje Uchenna
J Langseth Abraham
Original Assignee
Springworks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworks Therapeutics Inc filed Critical Springworks Therapeutics Inc
Publication of CL2024002760A1 publication Critical patent/CL2024002760A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación se refiere a métodos para tratar neurofibromas cutáneos (cNF) que comprende administrar a un paciente que lo necesita mirdametinib o una sal farmacéuticamente aceptable de este.
CL2024002760A 2022-03-17 2024-09-13 Tratamiento de neurofibromas cutáneos con mirdametinib CL2024002760A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263321046P 2022-03-17 2022-03-17
US202263321036P 2022-03-17 2022-03-17

Publications (1)

Publication Number Publication Date
CL2024002760A1 true CL2024002760A1 (es) 2025-01-31

Family

ID=88024469

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2024002763A CL2024002763A1 (es) 2022-03-17 2024-09-13 Dosificación no lineal de mirdametinib
CL2024002764A CL2024002764A1 (es) 2022-03-17 2024-09-13 Tratamiento de neurofibromas plexiformes asociados a neurofibromatosis tipo 1 (nf1) en pacientes pediátricos con mirdametinib
CL2024002766A CL2024002766A1 (es) 2022-03-17 2024-09-13 Tratamiento con mirdametinib
CL2024002760A CL2024002760A1 (es) 2022-03-17 2024-09-13 Tratamiento de neurofibromas cutáneos con mirdametinib

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CL2024002763A CL2024002763A1 (es) 2022-03-17 2024-09-13 Dosificación no lineal de mirdametinib
CL2024002764A CL2024002764A1 (es) 2022-03-17 2024-09-13 Tratamiento de neurofibromas plexiformes asociados a neurofibromatosis tipo 1 (nf1) en pacientes pediátricos con mirdametinib
CL2024002766A CL2024002766A1 (es) 2022-03-17 2024-09-13 Tratamiento con mirdametinib

Country Status (13)

Country Link
US (19) US20230293463A1 (es)
EP (4) EP4493174A4 (es)
JP (4) JP2025508196A (es)
KR (4) KR20240162067A (es)
CN (2) CN118984701A (es)
AU (4) AU2023234587A1 (es)
CA (4) CA3254428A1 (es)
CL (4) CL2024002763A1 (es)
CO (4) CO2024012870A2 (es)
IL (4) IL315402A (es)
MX (4) MX2024011250A (es)
PE (4) PE20242178A1 (es)
WO (4) WO2023178269A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3254428A1 (en) * 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. TREATMENT OF PLEXIFORM NEUROFIBROMAS (NP) ASSOCIATED WITH TYPE 1 NEUROFIBROMATOSIS (NF1) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB
WO2024192388A1 (en) * 2023-03-16 2024-09-19 SpringWorks Therapeutics Inc. Dosage forms of mirdametinib
KR20250160454A (ko) 2023-03-16 2025-11-13 스프링웍스 테라퓨틱스, 인크. 미르다메티닙의 투여 형태
WO2026006012A1 (en) * 2024-06-25 2026-01-02 Springworks Therapeutics, Inc. Dosing scheme for mirdametinib treatment
WO2026006011A1 (en) * 2024-06-25 2026-01-02 Springworks Therapeutics, Inc. Dosing scheme for mirdametinib treatment
US20250387351A1 (en) 2024-06-25 2025-12-25 SpringWorks Therapeutics, Inc Mirdametinib treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ546011A (en) * 2003-10-21 2009-09-25 Warner Lambert Co Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
CN103748085A (zh) * 2011-06-09 2014-04-23 诺华股份有限公司 杂环磺酰胺衍生物
GB201320729D0 (en) * 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
PT3624796T (pt) * 2017-05-19 2025-06-02 Nflection Therapeutics Inc Compostos de pirrolopiridina-anilina para tratamento de distúrbios dérmicos
WO2020106304A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Topical formulations
MX2022006366A (es) * 2019-11-27 2022-06-22 Turning Point Therapeutics Inc Terapia de combinacion que implica compuestos de diarilo macrociclico.
AU2021246141A1 (en) * 2020-04-03 2022-12-01 Beigene, Ltd. Co-administration of mirdametinib and lifirafenib for use in treating cancers
US11066358B1 (en) * 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11084780B1 (en) * 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
CA3254428A1 (en) 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. TREATMENT OF PLEXIFORM NEUROFIBROMAS (NP) ASSOCIATED WITH TYPE 1 NEUROFIBROMATOSIS (NF1) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB
KR20250160454A (ko) 2023-03-16 2025-11-13 스프링웍스 테라퓨틱스, 인크. 미르다메티닙의 투여 형태

Also Published As

Publication number Publication date
EP4493174A1 (en) 2025-01-22
US20230293462A1 (en) 2023-09-21
US20240226037A1 (en) 2024-07-11
EP4493175A4 (en) 2025-08-20
US20240058282A1 (en) 2024-02-22
IL315402A (en) 2024-11-01
KR20240162094A (ko) 2024-11-14
AU2023234587A1 (en) 2024-10-03
US20240000731A1 (en) 2024-01-04
CA3254428A1 (en) 2023-09-21
KR20240162067A (ko) 2024-11-14
US12295925B2 (en) 2025-05-13
AU2023236367A1 (en) 2024-10-03
US20230293472A1 (en) 2023-09-21
US11806322B2 (en) 2023-11-07
CA3255686A1 (en) 2023-09-21
EP4493538A1 (en) 2025-01-22
CL2024002766A1 (es) 2025-02-07
PE20242178A1 (es) 2024-11-07
US20230321014A1 (en) 2023-10-12
US11806321B2 (en) 2023-11-07
CO2024013937A2 (es) 2024-10-31
EP4493539A1 (en) 2025-01-22
IL315403A (en) 2024-11-01
EP4493538A4 (en) 2025-08-20
CA3254258A1 (en) 2023-09-21
EP4493174A4 (en) 2025-08-20
CL2024002763A1 (es) 2025-02-14
KR20240162517A (ko) 2024-11-15
US20240216306A1 (en) 2024-07-04
EP4493539A4 (en) 2025-08-20
US11883375B2 (en) 2024-01-30
US12324791B2 (en) 2025-06-10
EP4493175A1 (en) 2025-01-22
CO2024012872A2 (es) 2024-10-10
CO2024013947A2 (es) 2024-11-18
MX2024011142A (es) 2024-09-19
CL2024002764A1 (es) 2025-02-14
WO2023178262A1 (en) 2023-09-21
PE20242201A1 (es) 2024-11-19
WO2023178256A1 (en) 2023-09-21
IL315404A (en) 2024-11-01
US20250268850A1 (en) 2025-08-28
US20230321013A1 (en) 2023-10-12
AU2023233745A1 (en) 2024-10-03
US20240173274A1 (en) 2024-05-30
JP2025508196A (ja) 2025-03-21
IL315406A (en) 2024-11-01
MX2024011250A (es) 2024-09-23
US20240307329A1 (en) 2024-09-19
US20250275932A1 (en) 2025-09-04
CN119156372A (zh) 2024-12-17
US20240216305A1 (en) 2024-07-04
US20250090484A1 (en) 2025-03-20
JP2025509659A (ja) 2025-04-11
MX2024011403A (es) 2024-09-23
US20240307330A1 (en) 2024-09-19
WO2023178269A1 (en) 2023-09-21
CN118984701A (zh) 2024-11-19
JP2025508195A (ja) 2025-03-21
PE20242200A1 (es) 2024-11-19
US20240307328A1 (en) 2024-09-19
CA3254598A1 (en) 2023-09-21
US11839595B2 (en) 2023-12-12
US12257215B2 (en) 2025-03-25
JP2025509772A (ja) 2025-04-11
US12263146B2 (en) 2025-04-01
US20250170077A1 (en) 2025-05-29
WO2023178254A1 (en) 2023-09-21
PE20242202A1 (es) 2024-11-19
MX2024011249A (es) 2024-09-23
CO2024012870A2 (es) 2024-10-10
US20230293466A1 (en) 2023-09-21
US20230293463A1 (en) 2023-09-21
AU2023234590A1 (en) 2024-10-03
US12011424B2 (en) 2024-06-18
US11819487B2 (en) 2023-11-21
US12220390B2 (en) 2025-02-11
KR20240162066A (ko) 2024-11-14

Similar Documents

Publication Publication Date Title
CO2024012870A2 (es) Tratamiento de neurofibromas cutáneos con mirdametinib
MX2022012714A (es) Inhibidores de la replicacion de norovirus y coronavirus.
MX2022005994A (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
CL2023002497A1 (es) Uso de inhibidores de bet como tratamiento para la mielofibrosis
AR055038A1 (es) Metodo y compuesto para tratar enfermedades vasculares perifericas
CL2022002592A1 (es) Uso de agentes para el tratamiento de condiciones respiratorias
CL2024000466A1 (es) Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil
AR119158A1 (es) Tratamientos de angioedema hereditario
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
CL2024001351A1 (es) Composiciones y tratamientos con nirogacestat
CO5590913A2 (es) Terapia de combinacion antivirica
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
PE20230996A1 (es) Metodo para el tratamiento de afecciones asociadas a covid-19
MX2025013118A (es) Tratamiento combinado para una enfermedad o un trastorno relacionado con ras
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
RU2009101026A (ru) Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии
CO2025006782A2 (es) Composición farmacéutica para la prevención o tratamiento contra úlcera péptica relacionada a fármacos, que comprende zastaprazán o una sal farmacéuticamente aceptable del mismo
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
AR131842A1 (es) Métodos para tratar gliomas
RU2012151952A (ru) Способ создания плевродеза
UY39593A (es) Tratamiento para tumores sólidos malignos
AR132852A1 (es) Combiterapia para tratar el cáncer
PE20242177A1 (es) Tratamiento del glioma de bajo grado con mirdametinib
MX2021016090A (es) Lemborexant para el tratamiento de problemas del sueño.